Gender Male
Mr. King started his biotech career at Wyeth Pharmaceuticals working on Enbrel® before he joined Alexion Pharmaceuticals, where he was Vice President, U.S. Neurology Business Unit responsible for building and leading the commercial team and strategy that launched Soliris®(eculizumab) into the generalized Myasthenia Gravis market as the first
approved biologic and complement inhibitor. At Alexion, he also served as Vice President, Head of Global Hematology Franchise, among other leadership roles. He then joined Ra Pharma as the Chief Commercial Officer where he played a crucial role as part of the executive team in developing the commercial strategy for its C5 complement inhibitor in gMG and in its acquisition by UCB for $2.5 billion. Most recently, Mr. King was the Chief Commercial Officer at Vor Bio where he led commercial planning and business development for engineered cell therapies for patients with blood cancer. He began his career at Ernst & Young LLP and holds a Bachelor of Science in Business Logistics and a Master of Business Administration from Pennsylvania State University.
